SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
patients for affordable drugs now
Patient Advocates Warn Trump Pharma Tariffs Could 'Drive Up Costs and Create More Uncertainty'
One campaigner urged the administration to "focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Apr 02, 2026
On Thursday, the one-year anniversary of President Donald Trump's so-called Liberation Day, US advocacy groups sounded the alarm about his new tariffs targeting "patented pharmaceuticals and their ingredients under Section 232 of the Trade Expansion Act of 1962 to bolster American national security and public health."
The administration announced a year ago that the US Department of Commerce would conduct a related investigation under that law. The resulting report was recently sent to the president, and although the findings have not been made public, Trump's executive order summarizes key takeaways and Secretary Howard Lutnick's recommended actions.
According to the order, the secretary's recommendations included "continuing to negotiate onshoring agreements related to most favored nation (MFN) pharmaceutical pricing agreements; imposing significant tariffs on pharmaceuticals and pharmaceutical ingredients, so that such imports will not threaten to impair the national security of the United States; and granting preferential treatment to those companies that commit to onshore production of pharmaceuticals and pharmaceutical ingredients."
Citing an unnamed Trump administration official, The Washington Post reported Thursday that "the White House has reached agreements with 13 drugmakers and expects to soon conclude an additional four." As part of these deals, companies are planning to invest at least $400 billion in new US plants.
The Post also pointed out that "some imported drugs will face much lower tariffs under trade deals Trump negotiated with five US trading partners. Goods from the European Union, Japan, South Korea, and Switzerland will face 15% levies, while drugs from the United Kingdom, which was the first to sign a deal with Trump, will be hit with a 10% tariff."
Thanks to Trump's new order, brand-name pharmaceuticals made in other countries could be hit with tariffs as high as 100%.
Merith Basey, CEO of Patients for Affordable Drugs, warned in a statement that "while these tariffs aim to pressure pharmaceutical corporations into US manufacturing and most favored nation agreements, the current MFN deals remain opaque and voluntary, and have not delivered meaningful savings for the vast majority of American patients. There's a real risk these tariffs will drive up costs and create more uncertainty for millions of patients already struggling to afford their medications."
Experts at Public Citizen, another advocacy group that has sued to expose the secretive MFN agreements, were similarly critical.
"By announcing these tariffs without even producing the evidence from the investigation that supposedly justifies them, Trump is continuing his pattern of grabbing headlines by using the word 'tariff' while engaging in secretive ongoing negotiations and opaque exemptions processes that are ripe for corporate corruption," said Public Citizen Global Trade Watch director Melinda St. Louis—who also wrote a broader takedown of Trump's trade policy published Thursday by Common Dreams.
"While strategic tariffs can be used to support domestic manufacturing and good jobs, they must be paired with real public investments and support for workers' rights, which Trump has systematically undermined," she said. "Instead, he's bullying other countries like the UK into paying more for medicines, which will lead to windfall profits for Big Pharma and do nothing to reduce US prices."
Peter Maybarduk, director of Access to Medicines at Public Citizen, stressed that "Trump's tariffs will be either ineffective or harmful for what people need, which is a reliable, plentiful, affordable supply of medicine."
Also taking aim at the "secretive arrangements that allow Trump to claim specious victories on manufacturing and high drug prices," Maybarduk explained that "in reality, many manufacturing commitments claimed under the deals were part of previously planned projects and the drug pricing commitments appear designed to largely spare drug company profits rather than earnestly address affordability concerns."
"Meanwhile the administration has given drugmakers perks like lucrative vouchers to accelerate FDA review of their medicines and a promise from the Trump administration that it will bully other countries into adopting higher prescription drug prices, using tariffs as leverage," he continued, referring to the Food and Drug administration.
"If the administration wants to fix problems like medicines shortages and fragile supply chains," he argued, "it should focus on real solutions to support more transparent and diverse supply sources and make targeted investments for the supply of key medicines."
Keep ReadingShow Less
As TrumpRx Scam Does Virtually Nothing, Big Pharma Jacks Up Prices on Cancer Drugs
"As they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them, and patients are paying the price."
Mar 23, 2026
A report released Monday found that Big Pharma has continued raising prices on dozens of cancer drugs, despite President Donald Trump's repeated false claims that he and his administration have slashed drug prices by a mathematically impossible 600%.
The analysis, conducted by Patients for Affordable Drugs, found that pharmaceutical companies increased prices on 64 oncology drugs in the first weeks of 2026, with the vast majority of price hikes coming in above the rate of inflation.
Patients for Affordable Drugs noted the heavy financial toll that paying for treatments takes on US cancer patients, and said the latest price increases would only exacerbate the crisis.
"Cancer drugs are among the most expensive drugs on the market, costing $74,000 more on average than non-cancer drugs," the group explained. "More than 42% of cancer patients in the US fully depleted their savings within two years of diagnosis to cover their care. More than half of Americans with cancer go into debt because of the cost of their care."
Making matters worse, the group added, is that Big Pharma is heavily lobbying Congress to pass legislation that would further delay small molecule drugs, including "widely used, high-cost cancer treatments," from becoming eligible for Medicare price negotiations.
Merith Basey, CEO of Patients for Affordable Drugs, stressed that the latest price increases were unacceptable given that "cancer is a leading cause of death among American seniors, and the treatments patients rely on are already among the most expensive."
"Yet as they continue to hike prices, the pharmaceutical industry is also working overtime to block reforms that would lower them," added Basey, "and patients are paying the price."
While the Patients for Affordable Drugs report focuses on cancer drugs, a December report from Reuters found that at least 350 branded medications are set for price hikes in 2026, including “vaccines against Covid, RSV, and shingles,” as well as the “blockbuster cancer treatment Ibrance.”
The total projected number of drugs seeing price increases in 2026 is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications. The median price increase for drugs in 2026 is projected at 4%, roughly the same as in 2025.
All of these price increases have come despite Trump's false claims that he has lowered the prices of drugs to the point where pharmaceutical companies would actually be paying patients to take them.
An analysis released last week by the Center for American Progress (CAP) found that the president's TrumpRx initiative, which was created to purportedly offer Americans cheaper prescription drugs, offered genuinely lower prices on "exactly one" of the 54 medications listed on its website.
CAP also found that nearly one-third of the drugs available on the TrumpRx website have generic alternatives that were cheaper than what was being offered, and that the website made no mention of this.
Keep ReadingShow Less
As Trump Claims He's Slashing Costs, Big Pharma Jacks Up Prices on 350 Drugs
One critic charged that Trump's earlier deals with pharmaceutical companies "just nibble around the margins in terms of what is really driving high prices for prescription drugs in the US."
Dec 31, 2025
President Donald Trump in recent months has made ludicrously false claims about his administration slashing prescription drug prices in the US by as much as 600%, which would entail pharmaceutical companies paying people to use their products.
In reality, reported Reuters on Wednesday, drugmakers are planning to raise prices on hundreds of drugs in 2026.
Citing data from healthcare research firm 3 Axis Advisors, Reuters wrote that at least 350 branded medications are set for price hikes next year, including "vaccines against COVID, RSV, and shingles," as well as the "blockbuster cancer treatment Ibrance."
The total projected number of drugs seeing price increases next year is significantly higher than in 2025, when 3 Axis Advisors estimated that pharmaceutical companies raised prices on 250 medications.
The median price increase for drugs next year is projected at 4%, roughly the same as in 2025.
Reuters also found that some of the companies raising prices on their drugs are the same ones who struck deals with Trump to lower the costs of a limited number of prescriptions earlier this year, including Novartis, Pfizer, Boehringer Ingelheim, and GSK.
In announcing the deals with the pharmaceutical companies, Trump declared that "starting next year, American drug prices will come down fast and furious and will soon be the lowest in the developed world."
But Dr. Benjamin Rome, a health policy researcher at Brigham and Women's Hospital in Boston, told Reuters that the projected savings for Americans under the Trump deals are a drop in the bucket compared with the continued price hikes on other drugs.
"These deals are being announced as transformative when, in fact, they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the US," Rome explained.
Merith Basey, CEO of Patients For Affordable Drugs Now, a patient advocacy organization focused exclusively on lowering the cost of medications, also said she was unimpressed by Trump's deals with drugmakers.
"Voluntary agreements with drug companies—especially when key details remain undisclosed—are no substitute for durable, system-wide reforms," she said earlier this month. "Patients are overwhelmingly calling on Congress to do more to lower prescription drug prices by holding Big Pharma accountable and addressing the root causes of high drug prices, because drugs don’t work if people can’t afford them."
Keep ReadingShow Less
Most Popular